We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

Back to rankings

126 hedge funds and large institutions have $1B invested in Five Prime Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

36% more capital invested

Capital invested by funds: $737M → $1B (+$264M)

2% more funds holding

Funds holding: 123 → 126 (+3)

12% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 42

12% less call options, than puts

Call options by funds: $6.62M | Put options by funds: $7.52M

Holders
126
Holders Change
+3
Holders Change %
+2.44%
% of All Funds
3.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
37
Reduced
42
Closed
12
Calls
$6.62M
Puts
$7.52M
Net Calls
-$898K
Net Calls Change
+$130K

Top Buyers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
+$31.7M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$4.99M
3
Millennium Management
Millennium Management
New York
+$4.38M
4
Axa
Axa
France
+$4.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.79M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$11.3M
2
State Street
State Street
Massachusetts
-$10.9M
3
MWNA
Marshall Wace North America
New York
-$8.6M
4
Deutsche Bank
Deutsche Bank
Germany
-$6.61M
5
Goldman Sachs
Goldman Sachs
New York
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
126
Hudson Bay Capital Management
Connecticut
– -$1.35M -45,000 Closed
GCP
127
GSA Capital Partners
United Kingdom
– -$828K -27,500 Closed
Capital Fund Management (CFM)
128
Capital Fund Management (CFM)
France
– -$416K -13,819 Closed
EIM
129
Essex Investment Management
Massachusetts
– -$382K -12,692 Closed
SAM
130
Shell Asset Management
Netherlands
– -$377K -12,534 Closed
OAM
131
Oxford Asset Management
United Kingdom
– -$318K -10,565 Closed
PAM
132
Paradigm Asset Management
New York
– -$247K -8,200 Closed
Jane Street
133
Jane Street
New York
– -$201K -6,677 Closed
DSI
134
Daiwa SB Investments
Japan
– -$142K -4,700 Closed
PAM
135
Panagora Asset Management
Massachusetts
– -$86K -2,861 Closed
DADC
136
D.A. Davidson & Co
Montana
– -$18K -622 Closed
WCBA
137
Weaver C. Barksdale & Associates
Tennessee
– -$2K -56 Closed
PNC Financial Services Group
138
PNC Financial Services Group
Pennsylvania
– +$188 +6 New
2 3 4 5
6

FPRX Hedge Fund Activity: Q3 2017 in Review

126 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2017, worth a combined $1B — up 36% from $737M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FPRX positions and 12 closed out — a net gain of 5 holders — while 37 added to existing stakes and 42 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $31.7M. The largest seller was Renaissance Technologies, cutting an estimated $11.3M.

  • 126 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2017, up from 123 in Q2 2017.
  • Funds reported $1B of Five Prime Therapeutics, Inc. stock for Q3 2017, up 36% quarter-over-quarter.
  • 17 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2017 and 12 closed out, a net change of +5 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q3 2017 was HealthCor Management, an estimated $31.7M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q3 2017 was Renaissance Technologies, an estimated $11.3M sold.

Based on aggregated 13F filings for Q3 2017.